Clinical Trial

Pharmacogenomics of antiVEGF in Patients With Age-Associated Macular Degeneration (AMD)

Study acronym: AMD
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated November 20, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a phase III, multicenter, randomized double-blinded clinical trial with two parallel groups (ranibizumab and bevacizumab) and an observational follow-up of patients who meet elegibility criteria and decline participation due to treatment randomization. It will be performed involving 630 eyes from patients with wet age-related macular degeneration (wAMD) diagnosis without another eye disease. This clinical trial compares the treatment response for 3 years, considering genetic variants already studied between the eyes treated with one of the first options of anti-VEGF used in patients with wAMD, (ranibizumab) and the most cost-effective anti-VEGF (bevacizumab; off-label use)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-23; most recent amendment 2025-11-19.
Trial Details
NCT Number NCT06952452
Lead Sponsor Parc de Salut Mar
Collaborators: Instituto de Salud Carlos III
Conditions Wet Age-related Macular Degeneration
Enrollment 630 participants
Start Date 2022-11-18
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-11-20